These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23743853)

  • 1. Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.
    Said-Conti V; Amrolia PJ; Gaze MN; Stoneham S; Sebire N; Shroff R; Marks SD
    Pediatr Nephrol; 2013 Oct; 28(10):2053-6. PubMed ID: 23743853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
    Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H
    Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conservative management of post-transplant central nervous system lymphoma.
    Valavoor SH; Ashraf Z; Narwal R; Ratnam S
    Int Urol Nephrol; 2013 Aug; 45(4):1219-22. PubMed ID: 22476860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus.
    Tsang HH; Trendell-Smith NJ; Wu AK; Mok MY
    Lupus; 2010 Mar; 19(3):330-3. PubMed ID: 19897521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report.
    Abbassi M; Riley R; Malkin M; Tang Y; Rajendran B; Yazbeck V
    Exp Clin Transplant; 2019 Feb; 17(1):111-114. PubMed ID: 28447926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
    Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.
    Patrick A; Wee A; Hedderman A; Wilson D; Weiss J; Govani M
    J Neurooncol; 2011 Jul; 103(3):739-43. PubMed ID: 20872273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid.
    Boersma MN; van der Zanden A; Laverman GD; Sanders JS; de Vries PA
    Transpl Int; 2012 Nov; 25(11):e113-6. PubMed ID: 22909403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K; Pokala H; Ardura MI; Harker-Murray P; Johnson-Welch SF; Weinberg A; Seikaly M
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
    Banks CA; Meier JD; Stallworth CR; White DR
    Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.